Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed

VCYT among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+16.0%53rd of 155 · median +10.5%
Net margin
-4.1%15.3%
21.8%22nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
8.9%74th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
27.8%13th of 145 · median 10.0%

VCYT and 9 peers, year by year

The 9 Health care companies closest to VCYT in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
VCYT Veracyte, Inc. FY2025 $517.1M+16.0%70.1%11.2%12.8%24.5%5.1%-
PTGX Protagonist Therapeutics, Inc FY2025 $46.0M−89.4%-−343.6%−282.8%121.9%−21.2%-
ADMA Adma Biologics, Inc. FY2025 $510.2M+19.6%57.4%37.5%28.8%5.5%30.8%0.15
UFPT UFP Technologies Inc FY2025 $602.8M+19.5%28.3%15.3%11.3%-16.1%0.32
MIRM Mirum Pharmaceuticals, Inc. FY2025 $521.3M+54.7%-−4.2%−4.5%10.5%−7.4%-
TARS Tarsus Pharmaceuticals, Inc. FY2025 $451.4M+147%-−15.7%−14.7%−4.9%−19.3%0.21
GKOS GLAUKOS Corp FY2025 $507.4M+32.3%55.7%−39.3%−37.0%−4.4%−28.6%-
KRYS Krystal Biotech, Inc. FY2025 $389.1M+33.9%-41.5%52.6%48.5%16.8%-
WGS GeneDx Holdings Corp. FY2025 $427.5M+40.0%69.7%−3.1%−4.9%3.3%−6.8%0.18
ZLAB Zai Lab Ltd FY2025 $460.2M+15.0%-−49.9%−38.1%−34.5%−24.5%0.29

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

VCYTVeracyte, Inc.
FY2016 revenue $65.1MFY2017 revenue $72.0MFY2018 revenue $92.0MFY2019 revenue $120.4MFY2020 revenue $117.5MFY2021 revenue $219.5MFY2022 revenue $296.5MFY2023 revenue $361.1MFY2024 revenue $445.8MFY2025 revenue $517.1M FY2016 net margin −48.2%FY2017 net margin −43.1%FY2018 net margin −25.0%FY2019 net margin −10.5%FY2020 net margin −29.7%FY2021 net margin −34.4%FY2022 net margin −12.3%FY2023 net margin −20.6%FY2024 net margin 5.4%FY2025 net margin 12.8% FY2016FY2025
Revenue$517.1M Growth+16.0% Net margin12.8%
PTGXProtagonist Therapeutics, Inc
FY2017 revenue $20.1MFY2018 revenue $30.9MFY2019 revenue $231KFY2020 revenue $28.6MFY2021 revenue $27.4MFY2022 revenue $26.6MFY2023 revenue $60.0MFY2024 revenue $434.4MFY2025 revenue $46.0M FY2017 net margin −184.2%FY2018 net margin −125.9%FY2020 net margin −231.1%FY2021 net margin −458.9%FY2022 net margin −479.3%FY2023 net margin −131.6%FY2024 net margin 63.3%FY2025 net margin −282.8% FY2016FY2025
Revenue$46.0M Growth−89.4% Net margin−282.8%
ADMAAdma Biologics, Inc.
FY2016 revenue $10.7MFY2017 revenue $22.8MFY2018 revenue $17.0MFY2019 revenue $29.3MFY2020 revenue $42.2MFY2021 revenue $80.9MFY2022 revenue $154.1MFY2023 revenue $258.2MFY2024 revenue $426.5MFY2025 revenue $510.2M FY2016 net margin −183.1%FY2017 net margin −192.3%FY2018 net margin −387.1%FY2019 net margin −164.5%FY2020 net margin −179.4%FY2021 net margin −88.5%FY2022 net margin −42.8%FY2023 net margin −10.9%FY2024 net margin 46.4%FY2025 net margin 28.8% FY2016FY2025
Revenue$510.2M Growth+19.6% Net margin28.8%
UFPTUFP Technologies Inc
FY2016 revenue $146.1MFY2017 revenue $147.8MFY2018 revenue $190.5MFY2019 revenue $198.4MFY2020 revenue $179.4MFY2021 revenue $206.3MFY2022 revenue $353.8MFY2023 revenue $400.1MFY2024 revenue $504.4MFY2025 revenue $602.8M FY2016 net margin 5.5%FY2017 net margin 6.2%FY2018 net margin 7.5%FY2019 net margin 10.0%FY2020 net margin 7.5%FY2021 net margin 7.7%FY2022 net margin 11.8%FY2023 net margin 11.2%FY2024 net margin 11.7%FY2025 net margin 11.3% FY2016FY2025
Revenue$602.8M Growth+19.5% Net margin11.3%
MIRMMirum Pharmaceuticals, Inc.
FY2021 revenue $19.1MFY2022 revenue $77.1MFY2023 revenue $186.4MFY2024 revenue $336.9MFY2025 revenue $521.3M FY2021 net margin −438.9%FY2022 net margin −176.0%FY2023 net margin −87.7%FY2024 net margin −26.1%FY2025 net margin −4.5% FY2016FY2025
Revenue$521.3M Growth+54.7% Net margin−4.5%
TARSTarsus Pharmaceuticals, Inc.
FY2021 revenue $57.0MFY2022 revenue $25.8MFY2023 revenue $17.4MFY2024 revenue $183.0MFY2025 revenue $451.4M FY2021 net margin −24.2%FY2022 net margin −240.5%FY2023 net margin −778.9%FY2024 net margin −63.2%FY2025 net margin −14.7% FY2016FY2025
Revenue$451.4M Growth+147% Net margin−14.7%
GKOSGLAUKOS Corp
FY2016 revenue $114.4MFY2017 revenue $159.3MFY2018 revenue $181.3MFY2019 revenue $237.0MFY2020 revenue $225.0MFY2021 revenue $294.0MFY2022 revenue $282.9MFY2023 revenue $314.7MFY2024 revenue $383.5MFY2025 revenue $507.4M FY2016 net margin 4.0%FY2017 net margin −0.1%FY2018 net margin −7.1%FY2019 net margin 6.5%FY2020 net margin −53.5%FY2021 net margin −16.9%FY2022 net margin −35.1%FY2023 net margin −42.8%FY2024 net margin −38.2%FY2025 net margin −37.0% FY2016FY2025
Revenue$507.4M Growth+32.3% Net margin−37.0%
KRYSKrystal Biotech, Inc.
FY2023 revenue $50.7MFY2024 revenue $290.5MFY2025 revenue $389.1M FY2023 net margin 21.6%FY2024 net margin 30.7%FY2025 net margin 52.6% FY2016FY2025
Revenue$389.1M Growth+33.9% Net margin52.6%
WGSGeneDx Holdings Corp.
FY2019 revenue $196.2MFY2020 revenue $179.3MFY2021 revenue $212.2MFY2022 revenue $234.7MFY2023 revenue $202.6MFY2024 revenue $305.4MFY2025 revenue $427.5M FY2019 net margin −15.1%FY2020 net margin −134.6%FY2021 net margin −115.6%FY2022 net margin −233.9%FY2023 net margin −86.8%FY2024 net margin −17.1%FY2025 net margin −4.9% FY2016FY2025
Revenue$427.5M Growth+40.0% Net margin−4.9%
ZLABZai Lab Ltd
FY2018 revenue $129KFY2019 revenue $13.0MFY2020 revenue $49.0MFY2021 revenue $144.3MFY2022 revenue $215.0MFY2023 revenue $266.7MFY2024 revenue $399.0MFY2025 revenue $460.2M FY2020 net margin −549.3%FY2021 net margin −488.2%FY2022 net margin −206.1%FY2023 net margin −125.5%FY2024 net margin −64.4%FY2025 net margin −38.1% FY2016FY2025
Revenue$460.2M Growth+15.0% Net margin−38.1%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

$0 $602.8M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, $20.1M, $30.9M, $231K, $28.6M, $27.4M, $26.6M, $60.0M, $434.4M, $46.0M PTGX ADMA: $10.7M, $22.8M, $17.0M, $29.3M, $42.2M, $80.9M, $154.1M, $258.2M, $426.5M, $510.2M ADMA UFPT: $146.1M, $147.8M, $190.5M, $198.4M, $179.4M, $206.3M, $353.8M, $400.1M, $504.4M, $602.8M UFPT MIRM: -, -, -, -, $0, $19.1M, $77.1M, $186.4M, $336.9M, $521.3M MIRM TARS: -, -, -, -, $0, $57.0M, $25.8M, $17.4M, $183.0M, $451.4M TARS GKOS: $114.4M, $159.3M, $181.3M, $237.0M, $225.0M, $294.0M, $282.9M, $314.7M, $383.5M, $507.4M GKOS KRYS: -, -, -, -, -, $0, $0, $50.7M, $290.5M, $389.1M KRYS WGS: -, -, -, $196.2M, $179.3M, $212.2M, $234.7M, $202.6M, $305.4M, $427.5M WGS ZLAB: -, -, $129K, $13.0M, $49.0M, $144.3M, $215.0M, $266.7M, $399.0M, $460.2M ZLAB VCYT: $65.1M, $72.0M, $92.0M, $120.4M, $117.5M, $219.5M, $296.5M, $361.1M, $445.8M, $517.1M VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $602.8M. A gap is a year with no number. A ring marks where a line starts: PTGX, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−99.3% +949% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, -, +54.1%, −99.3%, n/m, −4.4%, −2.8%, +126%, +624%, −89.4% PTGX ADMA: +48.5%, +113%, −25.4%, +72.8%, +43.9%, +91.7%, +90.4%, +67.6%, +65.2%, +19.6% ADMA UFPT: +5.2%, +1.2%, +28.8%, +4.2%, −9.6%, +15.0%, +71.5%, +13.1%, +26.1%, +19.5% UFPT MIRM: -, -, -, -, -, -, +303%, +142%, +80.8%, +54.7% MIRM TARS: -, -, -, -, -, -, −54.7%, −32.4%, +949%, +147% TARS GKOS: +59.5%, +39.2%, +13.8%, +30.7%, −5.1%, +30.7%, −3.8%, +11.3%, +21.9%, +32.3% GKOS KRYS: -, -, -, -, -, -, -, -, +473%, +33.9% KRYS WGS: -, -, -, -, −8.6%, +18.3%, +10.6%, −13.7%, +50.8%, +40.0% WGS ZLAB: -, -, -, n/m, +277%, +194%, +47.6%, +25.4%, +49.1%, +15.0% ZLAB VCYT: +31.5%, +10.6%, +27.9%, +30.8%, −2.4%, +86.8%, +35.1%, +21.8%, +23.5%, +16.0% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −99.3% to +949%. A gap is a year with no number. A ring marks where a line starts: PTGX, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

−148.4% 86.8% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 ADMA: 40.3%, −28.1%, −148.4%, -, −45.2%, 1.4%, 22.9%, 34.4%, 51.5%, 57.4% ADMA UFPT: 23.7%, 24.0%, 25.4%, 27.2%, 24.9%, 24.8%, 25.5%, 28.1%, 29.1%, 28.3% UFPT GKOS: 85.9%, 86.8%, 86.2%, 83.7%, 59.2%, 77.3%, 75.6%, 76.0%, 75.5%, 55.7% GKOS WGS: -, -, -, 42.2%, 2.2%, −7.8%, −11.4%, 44.4%, 63.6%, 69.7% WGS ZLAB: -, -, 66.6%, -, -, -, -, -, -, - ZLAB VCYT: -, -, -, -, -, -, 59.2%, 63.6%, 66.9%, 70.1% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −148.4% to 86.8%. A gap is a year with no number. A ring marks where a line starts: VCYT, WGS, ZLAB have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
VCYT Dec ------59.2%63.6%66.9%70.1%
PTGX Dec ----------
ADMA Dec 40.3%−28.1%−148.4%-−45.2%1.4%22.9%34.4%51.5%57.4%
UFPT Dec 23.7%24.0%25.4%27.2%24.9%24.8%25.5%28.1%29.1%28.3%
MIRM Dec ----------
TARS Dec ----------
GKOS Dec 85.9%86.8%86.2%83.7%59.2%77.3%75.6%76.0%75.5%55.7%
KRYS Dec ----------
WGS Dec ---42.2%2.2%−7.8%−11.4%44.4%63.6%69.7%
ZLAB Dec --66.6%-------
Peer median40.3%24.0%46.0%42.2%13.6%13.1%24.2%39.4%57.6%56.6%

Operating margin, FY2016 to FY2025

Operating income / revenue.

−906.1% 58.2% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, −188.9%, −136.7%, n/m, −225.4%, −460.0%, −494.2%, −156.1%, 58.2%, −343.6% PTGX ADMA: −162.6%, −172.7%, −354.9%, −141.1%, −153.8%, −72.1%, −25.5%, 8.4%, 32.6%, 37.5% ADMA UFPT: 8.4%, 7.9%, 10.3%, 12.5%, 9.3%, 10.3%, 15.7%, 14.4%, 16.0%, 15.3% UFPT MIRM: -, -, -, -, -, −906.1%, −170.3%, −58.6%, −26.0%, −4.2% MIRM TARS: -, -, -, -, -, −21.3%, −242.9%, −820.5%, −65.9%, −15.7% TARS GKOS: 3.7%, −1.4%, −7.2%, −21.2%, −54.9%, −11.2%, −29.1%, −40.9%, −31.9%, −39.3% GKOS KRYS: -, -, -, -, -, -, -, −216.2%, 22.6%, 41.5% KRYS WGS: -, -, -, −15.5%, −134.9%, −210.3%, −284.5%, −89.2%, −7.6%, −3.1% WGS ZLAB: -, -, n/m, n/m, −616.4%, −485.1%, −188.0%, −137.4%, −70.7%, −49.9% ZLAB VCYT: −44.3%, −36.9%, −24.2%, −12.6%, −30.1%, −37.3%, −13.9%, −23.8%, 3.6%, 11.2% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −906.1% to 58.2%. A gap is a year with no number. A ring marks where a line starts: PTGX, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Net margin, FY2016 to FY2025

Net income / revenue.

−778.9% 63.3% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, −184.2%, −125.9%, n/m, −231.1%, −458.9%, −479.3%, −131.6%, 63.3%, −282.8% PTGX ADMA: −183.1%, −192.3%, −387.1%, −164.5%, −179.4%, −88.5%, −42.8%, −10.9%, 46.4%, 28.8% ADMA UFPT: 5.5%, 6.2%, 7.5%, 10.0%, 7.5%, 7.7%, 11.8%, 11.2%, 11.7%, 11.3% UFPT MIRM: -, -, -, -, -, −438.9%, −176.0%, −87.7%, −26.1%, −4.5% MIRM TARS: -, -, -, -, -, −24.2%, −240.5%, −778.9%, −63.2%, −14.7% TARS GKOS: 4.0%, −0.1%, −7.1%, 6.5%, −53.5%, −16.9%, −35.1%, −42.8%, −38.2%, −37.0% GKOS KRYS: -, -, -, -, -, -, -, 21.6%, 30.7%, 52.6% KRYS WGS: -, -, -, −15.1%, −134.6%, −115.6%, −233.9%, −86.8%, −17.1%, −4.9% WGS ZLAB: -, -, n/m, n/m, −549.3%, −488.2%, −206.1%, −125.5%, −64.4%, −38.1% ZLAB VCYT: −48.2%, −43.1%, −25.0%, −10.5%, −29.7%, −34.4%, −12.3%, −20.6%, 5.4%, 12.8% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −778.9% to 63.3%. A gap is a year with no number. A ring marks where a line starts: PTGX, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$567.5M $188.9M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: −$30.3M, $3.2M, −$50.4M, −$42.5M, −$73.0M, −$109.0M, −$108.9M, −$70.8M, $182.8M, $56.1M PTGX ADMA: −$18.3M, −$39.9M, −$64.8M, −$80.0M, −$114.7M, −$125.9M, −$73.4M, $4.0M, $110.4M, $27.8M ADMA UFPT: $2.1M, $7.1M, $15.9M, $25.5M, $20.7M, $8.9M, $4.0M, $30.8M, $56.9M, - UFPT MIRM: -, -, -, −$39.6M, −$89.3M, −$132.8M, −$120.4M, −$71.1M, $9.3M, $54.9M MIRM TARS: -, -, -, −$3.8M, −$21.6M, $3.2M, −$49.5M, −$119.0M, −$84.6M, −$22.3M TARS GKOS: $6.0M, $19.8M, $8.5M, −$5.1M, −$29.9M, −$23.1M, −$63.3M, −$78.0M, −$67.6M, −$22.5M GKOS KRYS: −$1.3M, −$4.1M, −$11.7M, −$25.1M, −$40.9M, −$116.3M, −$153.5M, −$100.6M, $119.2M, $188.9M KRYS WGS: -, -, -, −$30.7M, −$117.2M, −$199.8M, −$326.3M, −$185.4M, −$34.0M, $14.3M WGS ZLAB: −$34.4M, −$41.5M, −$107.6M, −$197.0M, −$226.2M, −$567.5M, −$392.2M, −$205.4M, −$220.5M, −$158.9M ZLAB VCYT: −$32.2M, −$25.7M, −$15.4M, −$6.0M, −$12.5M, −$37.0M, −$1.0M, $34.3M, $63.8M, $126.6M VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$567.5M to $188.9M. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS, WGS have no earlier 10-K here.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−693.8% 121.9% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, 16.0%, −163.1%, n/m, −254.8%, −398.3%, −409.8%, −118.1%, 42.1%, 121.9% PTGX ADMA: −172.1%, −175.5%, −381.4%, −272.6%, −271.7%, −155.5%, −47.6%, 1.6%, 25.9%, 5.5% ADMA UFPT: 1.4%, 4.8%, 8.3%, 12.8%, 11.5%, 4.3%, 1.1%, 7.7%, 11.3%, - UFPT MIRM: -, -, -, -, -, −693.8%, −156.3%, −38.1%, 2.8%, 10.5% MIRM TARS: -, -, -, -, -, 5.5%, −191.9%, −682.0%, −46.2%, −4.9% TARS GKOS: 5.3%, 12.4%, 4.7%, −2.1%, −13.3%, −7.8%, −22.4%, −24.8%, −17.6%, −4.4% GKOS KRYS: -, -, -, -, -, -, -, −198.4%, 41.0%, 48.5% KRYS WGS: -, -, -, −15.6%, −65.4%, −94.2%, −139.0%, −91.5%, −11.1%, 3.3% WGS ZLAB: -, -, n/m, n/m, −462.0%, −393.3%, −182.4%, −77.0%, −55.3%, −34.5% ZLAB VCYT: −49.5%, −35.7%, −16.7%, −5.0%, −10.7%, −16.9%, −0.3%, 9.5%, 14.3%, 24.5% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −693.8% to 121.9%. A gap is a year with no number. A ring marks where a line starts: PTGX, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−184.3% 56.6% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: −42.5%, −30.6%, −34.6%, −96.5%, −23.7%, −41.8%, −59.1%, −23.5%, 40.8%, −21.2% PTGX ADMA: n/m, −108.5%, n/m, −184.3%, −85.8%, −50.8%, −43.4%, −20.9%, 56.6%, 30.8% ADMA UFPT: 7.0%, 7.4%, 10.2%, 12.2%, 7.6%, 8.2%, 17.6%, 15.7%, 17.2%, 16.1% UFPT MIRM: -, -, -, −40.3%, −60.0%, −69.9%, −95.5%, −65.7%, −39.0%, −7.4% MIRM TARS: -, -, n/m, n/m, −16.2%, −8.3%, −32.2%, −69.0%, −51.5%, −19.3% TARS GKOS: 3.9%, −0.1%, −7.4%, 2.3%, −18.0%, −8.4%, −18.7%, −29.2%, −19.1%, −28.6% GKOS KRYS: n/m, −16.0%, −9.6%, −9.4%, −11.0%, −11.7%, −26.8%, 1.4%, 9.4%, 16.8% KRYS WGS: -, -, -, n/m, n/m, −63.2%, n/m, −77.1%, −21.3%, −6.8% WGS ZLAB: n/m, −21.4%, −55.4%, −66.2%, −23.0%, −51.1%, −42.4%, −42.0%, −30.6%, −24.5% ZLAB VCYT: −52.6%, −83.3%, −28.8%, −5.3%, −8.3%, −6.9%, −3.4%, −7.1%, 2.1%, 5.1% VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −184.3% to 56.6%. A gap is a year with no number. A ring marks where a line starts: ADMA, MIRM, TARS, KRYS, WGS, ZLAB have no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.00 1.05 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: -, -, -, 0.12, -, -, -, -, -, - PTGX ADMA: n/m, 0.07, 0.14, 0.00, 1.05, -, -, -, 0.21, 0.15 ADMA UFPT: 0.01, -, 0.18, -, 0.00, 0.39, 0.23, 0.11, 0.55, 0.32 UFPT TARS: -, -, -, -, -, 0.00, 0.10, 0.15, 0.32, 0.21 TARS WGS: -, -, -, -, n/m, 0.03, 0.04, 0.25, 0.23, 0.18 WGS ZLAB: -, -, 0.01, 0.02, -, -, -, 0.00, 0.16, 0.29 ZLAB VCYT: 0.42, 0.67, 0.32, 0.00, 0.00, 0.00, -, -, -, - VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 1.05. A gap is a year with no number. A ring marks where a line starts: PTGX, ADMA, TARS, WGS, ZLAB have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
VCYT Dec 0.420.670.320.000.000.00----
PTGX Dec ---0.12------
ADMA Dec n/m0.070.140.001.05---0.210.15
UFPT Dec 0.01-0.18-0.000.390.230.110.550.32
MIRM Dec ----------
TARS Dec -----0.000.100.150.320.21
GKOS Dec ----------
KRYS Dec ----------
WGS Dec ----n/m0.030.040.250.230.18
ZLAB Dec --0.010.02---0.000.160.29
Peer median--0.140.02-0.030.100.130.230.21

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$264056.00 $8.75 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 PTGX: −$5.80, −$2.09, −$1.74, −$2.98, −$1.92, −$2.71, −$2.60, −$1.39, $4.23, −$2.05 PTGX ADMA: −$1.61, −$1.91, −$1.45, −$0.89, −$0.88, −$0.51, −$0.33, −$0.13, $0.81, $0.60 ADMA UFPT: $1.10, $1.26, $1.93, $2.63, $1.77, $2.09, $5.45, $5.83, $7.58, $8.75 UFPT MIRM: -, -, -, −$4.58, −$4.09, −$2.77, −$4.02, −$4.00, −$1.85, −$0.47 MIRM TARS: -, -, -, −$1.98, −$4.32, −$0.67, −$2.52, −$4.62, −$3.07, −$1.59 TARS GKOS: $0.12, $0.00, −$0.37, $0.37, −$2.70, −$1.07, −$2.09, −$2.78, −$2.77, −$3.28 GKOS KRYS: −$1.31, −$1.48, −$0.97, −$1.20, −$1.71, −$3.13, −$5.49, $0.39, $3.00, $6.84 KRYS WGS: -, -, -, −$264056.00, −$47036.00, −$2.27, −$53.63, −$7.23, −$1.94, −$0.73 WGS ZLAB: −$3.97, −$2.32, −$2.64, −$3.03, −$0.35, −$0.76, −$0.46, −$0.35, −$0.26, −$0.16 ZLAB VCYT: −$1.09, −$0.91, −$0.62, −$0.27, −$0.66, −$1.11, −$0.51, −$1.02, $0.31, $0.82 VCYT
VCYT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$264056.00 to $8.75. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS, WGS have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out VCYT and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: VCYT's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.